1. Home
  2. CUE

CUE

Cue Biopharma Inc.

Logo Cue Biopharma Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-24-2024 2:15pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Founded: N/A Country:
N/A
Employees: N/A City: BOSTON
Market Cap: 75.9M IPO Year: 2018
Target Price: $9.50 AVG Volume (30 days): 258.5K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.11 EPS Growth: N/A
52 Week Low/High: $1.65 - $5.12 Next Earning Date: 01-01-0001
Revenue: $5,490,000 Revenue Growth: 340.96%
Revenue Growth (this year): -26.41% Revenue Growth (next year): N/A

Share on Social Networks: